Welcome to the ISCB Community News Blog

This blog collects news, announcements or other information which could be of interest to our ISCB members. We are a group ISCB members who volunteer to populate this blog on a regular basis. In case you want to become an "ISCB-News Reporter" yourself, let us know: contact ISCB
Don't repost copyrighted content! The guidelines are:
- Include a link to the source page
- Include a short summary about the article. You can quote up to ONE paragraph from the original story, but not more
- Don't repost an entire articles originating from another source
- Never post content without attribution — always include the source

To post a news, please use this form.

Monday, October 3, 2011

Genetic Engineering & Biotechnology News (GEN) Celebrates 30 years with Collector's Edition

For Immediate Release
Contact: Linda Muskat-Rim, 914-740-2251, lmuskat@liebertpub.com, Mary Ann Liebert, Inc., publishers

Genetic Engineering & Biotechnology News(GEN)
Celebrates 30 Years with 130-Page Collector's Edition

New Rochelle, NY, October 3, 2011— Genetic Engineering & Biotechnology News (GEN) celebrates 30 years as the world's
first and most widely read magazine for the biotechnology industry. Universally heralded as the definitive information
source in this field, GEN covers the technology, trends, products, services, and advances that shape and drive the industry
forward. GEN's 130-page commemorative issue features articles written by luminaries, and an original poster that
tracks the milestones that have altered the course of biotechnology, leading to today's most groundbreaking scientific and
therapeutic discoveries.

"Genetic Engineering & Biotechnology News was there at the inception of this field and remains the single most useful
resource I use for keeping abreast of new developments," said James Wilson, M.D., Ph.D., Professor of Pathology and
Laboratory Medicine, Gene Therapy Program, University of Pennsylvania School of Medicine.

GEN was founded in 1981 by Mary Ann Liebert, who identified the untapped need for a publication dedicated to the
rapidly evolving biotech industry from applied research through commercialization. David Weiner, Ph.D., Professor of
Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, said, "Mary Ann practically willed
the biotech revolution."

"GEN is biotechnology. It always has been and always will be," said Mary Ann Liebert, president and CEO of the
company that bears her name. John Sterling, GEN's Editor-in-Chief for the past 27 years, confirms that "Genetic
Engineering & Biotechnology News impacts the industry. It fosters critical international collaborations among academia,
industry, and government."

Publishing October 1, the Collector's Edition includes contributions from Leroy Hood, M.D., Ph.D., on Biological
Complexity Under Attack; James M. Wilson, M.D., Ph.D., on The History and Promise of Gene Therapy; Elaine R.
Mardis, Ph.D., on Future of DNA Sequencing Technology; Rita Colwell, Ph.D., on Combating Infectious Disease Agents;
N. Leigh Anderson, Ph.D., on Proteomics: Pathways and Biomarkers; G. Steven Burrill on Tracking Operational
Financing Trends; and articles on bioprocessing and synthetic biology.

Over the years, GEN's guest editorials have been penned by notables including: Presidents Bill Clinton and Jimmy Carter;
Vice Presidents Al Gore and Dan Quayle; Speaker of the House Newt Gingrich; Nobel Prize Winner and co-discoverer of
the structure of DNA, James D. Watson, Ph.D.; former Head of 20th Century Fox and Co-Founder of Stand Up To Cancer,
Sherry Lansing; and J. Craig Venter, Ph.D., leader of a team that decoded the human genome. GEN enjoyed its own
celebrity and a film credit as a scientific consultant for the hit film Jurassic Park.

Genetic Engineering & Biotechnology News is published in print 21 times a year. Its 24/7 website, www.genengnews.
com, provides exclusive editorial online, including news and analysis, podcasts, webinars, polls, videos, and application
notes. The publication's focus, both in print and online, includes the entire bioproduct life cycle from bench to bedside.
Biobusiness, drug discovery, OMICS, bioprocessing, and translational medicine form the core of GEN's global
biotechnology coverage.

GEN's Collector's Edition is available free to subscribers. For individual and bulk purchase contact: Nancy Piscitello

Contact Person: Linda Muskat-Rim (lmuskat@liebertpub.com)